Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.030 -0.060 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
From atai Life Sciences
Via GlobeNewswire
News headline image
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
News headline image
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth ↗
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position. 
Via Benzinga
News headline image
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From atai Life Sciences
Via GlobeNewswire
News headline image
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
News headline image
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies ↗
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
Via Benzinga
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗
 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
News headline image
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant ↗
Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targeting treatment-resistant patients. 
Via Benzinga
News headline image
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024 ↗
ATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
News headline image
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers ↗
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases. 
Via InvestorPlace
News headline image
3 Psychedelic Stocks to Ride to the Moon and Beyond ↗
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
Via InvestorPlace
News headline image
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. 
Via InvestorPlace
News headline image
3 Psychedelic Stocks to Buy on the Dip: Summer 2024 ↗
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. 
Via InvestorPlace
News headline image
Clinical-Stage BioTech Drug Stocks Declined 13% In June ↗
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
News headline image
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.